

The effects of cardiovascular rehabilitation in patients with reduced, mildly reduced, and preserved ejection fraction - do they benefit equally?

Milovan Stojanović^{1,2}, Marina Deljanin Ilić Marina^{1,2}, Stevan Ilić³

¹Institute for Treatment and Rehabilitation Niška Banja, Niš, Serbia. ²Faculty of Medicine, University of Niš, Serbia,

³Clinic for Internal Diseases CardioPoint, Niš, Serbia

Abstract

Background. Coronary artery disease (CAD) is the leading cause of heart failure (HF). The beneficial effects of cardiac rehabilitation (CR) in CAD patients are well known but whether they depend on ejection fraction (EF) is rather unknown.

Aim. To examine whether CAD pts with reduced, mildly reduced, and preserved EF benefit equally from comprehensive CR in terms of exercise tolerance.

Methods. 828 CAD pts attended a three-week CR program at the residential center. Before attending CR all patients underwent an echocardiographic exam after which pts were divided into three groups: heart failure with reduced (HFrEF≤40%), mildly reduced (HFmrEF 41-49%), and preserved EF (HFpEF≥50%). At baseline and at the end of CR exercise stress test (EST) was taken.

Results. There were 84 HFrEF pts (10.14%), 246 HFmrEF pts (29.71%), and 498 HFpEF pts (60.15%). At the first EST (EST1) and at the second EST (EST2) HFpEF and HFmrEF patients showed better strain tolerance compared to pts with HFrEF by reaching a higher strain levels and longer duration of EST. However, all three groups showed better strain tolerance at the EST2. Namely, they all reached higher strain level (for all three groups $p=0.000$) and longer duration of EST (for all three groups $p=0.000$). Also, in all three groups significantly higher percentage of patients reached submaximal heart rate at the EST2 compared to EST1 ($p=0.001$ for HFrEF, $p=0.006$ for HFmrEF, and $p=0.000$ for HFpEF). Pts with HFrEF had a significantly higher rate of arrhythmia at the EST2 compared to pts with HFmrEF and HFpEF ($p=0.009$). Improvement of physical strain level and duration of EST on EST2 compared with EST1 was more pronounced in pts with reduced (by 19,2% and 28,7%), than in pts with mildly reduced (by 13,9% and 17,5%) and pts with preserved LVEF (14,1% and 16,8%).

Conclusion. Results indicate that CR significantly improved physical strain tolerance in patients with coronary artery diseases independent of ejection fraction. In pts with HFmrEF and HFpEF CR resulted in higher level of strain tolerance than in pts with HFrEF. However, improvement in exercise capacity was more pronounced in pts with HFrEF.

Key words

coronary artery disease, heart failure, cardiovascular rehabilitation

Introduction

Heart failure (HF) is a clinical syndrome consisting of clinical signs and symptoms caused by structural or functional heart abnormalities that lead to reduced cardiac output or elevated intracardiac pressure¹. The prevalence of HF is 1-2%, but rises with age and appears to be higher than 10% in patients aged 70 years or older². The most common causes of HF are coronary artery disease (CAD) and arterial hypertension (HTA)¹.

HF is divided into three categories based on left ventricular ejection fraction (LVEF): HF with reduced EF (HFrEF) with EF ≤40%, HF with mildly reduced EF (HFmrEF) with EF 41-49%, and HF with preserved EF (HFpEF) with EF ≥50% (¹). About 1/2 of HF patients have HFrEF,

and the other half have HFmrEF or HFpEF³. It seems that patients with HFrEF have a worse prognosis compared to patients with HFmrEF or HFpEF¹. However, in many cases HFpEF and HFmrEF progress to HFrEF¹.

A well-designed cardiovascular rehabilitation (CVR) is of tremendous importance in the treatment of cardiovascular diseases and secondary prevention of cardiovascular events. It improves the quality of life, reduces the risk of secondary cardiovascular events and prolongs life⁴. Moreover, in CAD patients CVR reduces inflammation and oxidative stress⁵ and has a great impact on hemodynamics⁶. These positive effects are noted in both genders⁷. The latest European Association of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic HF give IA recommendation for exercise rehabilitation in all HF patients “who are able in

order to improve exercise capacity, quality of life, and reduce HF hospitalization¹¹. These recommendation is given for all three classes of HF, although there is no date on beneficial effects of CVR on patients with HFmrEF.

The aim of the study was to examine whether patients with coronary artery disease and reduced, mildly reduced, and preserved EF benefit equally from comprehensive cardiovascular rehabilitation in terms of exercise tolerance.

Methods

The study involved eight hundred twenty-eight CAD patients, 202 (24.4%) women and 626 (75.6%) men. All patients participated in a three-week CVR program at the Institute for Treatment and Rehabilitation "Niska Banja" after surviving myocardial infarction (MI), percutaneous coronary intervention or coronary artery bypass grafting (CABG). Before the beginning of CVR an echocardiographic exam was performed and all patients were divided into three groups: patients with HFrEF (84 patients, 10.14%), HFmrEF (246 patients, 29.71%), and HFpEF (498 patients, 60.15%). All patients belonged to New York Heart Association (NYHA) I-II class.

During a three-week CVR all patients underwent a dosed and individualized physical training which included bicycle riding, walking and cardiovascular exercise programs. At baseline and at the end of CVR exercise stress test (EST) was done. ESTs were performed on the treadmill (3017 Full Vision Drive, Newton, Kansas, USA) according to the Bruce protocol. Tests were limited by symptoms and signs like chest pain, lack of air, dizziness, etc., complex heart rhythm disorders, pathological changes on the electrocardiogram (ECG), or submaximal heart rate (calculated as 85% from 220-age equation). Pathological changes on ECG were defined as the occurrence of horizontal and/or down-sloping ST depression ≥ 01 mm. Complex heart rhythm disorders were defined as long-term episodes of bigeminy of ventricular

premature complex (VPC), couplets of VPC, and ventricular tachycardia. All data were collected, compared, and analyzed based on EF values.

Statistical analysis was performed using SPSS for Windows (Version 20; SPSS, Chicago, IL, USA). Frequencies and percentages were used for the description of the patient's characteristics. Numerical data were expressed as mean \pm standard deviation (SD). The Kolmogorov-Smirnov test was used to test the normality of data. Statistical significance for nominal data was tested with the χ^2 test and, where appropriate, the Fisher exact test. The Student's t-test was used to assess the statistical significance of parametric continuous data, and Mann-Whitney U-test and Wilcoxon Signed Ranks Test were for nonparametric continuous variables. The Pearson's correlation was used to determine the correlation between variables. Statistical significance was set to a level of $p < 0.05$.

Results

Women were more present in the group with HFpEF compared to the other two groups (27.51% vs. 19.51% HFmrEF, and 20.24% HFrEF), with statistically significant difference noted between HFmrEF and HFpEF ($p=0.37$). The age structure was similar in all three groups. Smokers were more present in group with HFmrEF (58.54%) compared to the group with HFpEF (48.19%) and HFrEF (52.38%), with statistically significant difference noted between HFmrEF and HFpEF ($p=0.033$). Other risk factors for cardiovascular diseases (hyperlipidemia, diabetes mellitus, arterial hypertension, heredity) did not differ between the groups (Table 1).

At the beginning of CVR, the first exercise stress tests (EST1) were performed. Patients with HFpEF showed better strain tolerance compared to HFrEF and HFmrEF as they achieved higher strain level. Also, EST1 lasted the longest in patients with HFpEF. On the other hand, patients with HFrEF showed the worse strain tolerance. For both parameter statistically significant differences

Table 1. Baseline characteristic of patients

EF $\leq 40\%$		Groups			Total	χ^2	p
		41%-49%	$\geq 50\%$				
Gender n (%)	Women	17 (20.24%)	48 (19.51%)	137 (27.51%)	202 (24.4%)	6.587	.037
	Men	67 (79.76%)	198 (80.49%)	361 (72.49%)	626 (75.6%)		
Hyperlipidaemia n (%)	No	9 (10.71%)	29 (11.79%)	46 (9.24%)	84 (10.14%)	1.209	.546
	Yes	75 (89.29%)	217 (88.21%)	452 (90.76%)	744 (89.86%)		
Hypertension n (%)	No	13 (15.48%)	32 (13.01%)	69 (13.86%)	114 (13.77%)	.329	.848
	Yes	71 (84.52%)	214 (86.99%)	429 (86.14%)	714 (86.23%)		
Diabetes mellitus n (%)	No	63 (75%)	184 (74.8%)	371 (74.5%)	618 (74.64%)	.014	.993
	Yes	21 (25%)	62 (25.2%)	127 (25.5%)	210 (25.36%)		
Heredity n (%)	No	57 (67.86%)	148 (60.41%)	294 (59.04%)	499 (60.34%)	2.338	.311
	Yes	27 (32.14%)	97 (39.59%)	204 (40.96%)	328 (39.66%)		
Smoking n (%)	No	40 (47.62%)	102 (41.46%)	257 (51.61%)	399 (48.19%)	6.797	.033
	Yes	44 (52.38%)	144 (58.54%)	241 (48.39%)	429 (51.81%)		
Age (m \pm sd)		61.93 \pm 10.01	59.78 \pm 9.75	60.79 \pm 9.6	60.61 \pm 9.69	3.856	.145

Table 2. The first exercise stress test (EST1)

EF ≤40%	Groups			Total	χ ²	p	
	41%-49%	≥50%					
Level	1.98±0.86	2.3±0.91	2.34±0.99	2.29±0.96	10.066	.007	
Duration (min)	4.32±2.43	5.42±2.48	5.52±2.69	5.37±2.63	15.086	.001	
DP before	9704.29±2030.22	10113.58±5310.56	9926.81±6664.13	9959.73±5955.86	2.620	.270	
DP after	19109.35±4272.01	22233.87±13138.37	21681.51±4005.08	21584.67±7960.08	24.689	.000	
SHR achieved n (%)	No	47 (55.95%)	103 (41.87%)	209 (41.97%)	359 (43.36%)	6.039	.049
	Yes	37 (44.05%)	143 (58.13%)	289 (58.03%)			
Arrhythmia n (%)	No	51 (89.47%)	143 (89.38%)	308 (91.12%)	502 (90.45%)	.455	.797
	Yes	6 (10.53%)	17 (10.63%)	30 (8.88%)			
Ischemic changes n (%)	No	80 (95.24%)	219 (89.39%)	434 (87.15%)	733 (88.63%)	4.865	.088
	Yes	4 (4.76%)	26 (10.61%)	64 (12.85%)			

DP – double product; SHR – submaximal heart rate.

were noted between HFmrEF and HFpEF on one hand, and HFrEF on the other ($p=0.007$ for level, and $p=0.001$ for duration). Also, a significantly greater percentage of patients with HFmrEF and HFpEF achieved submaximal heart rate at the end of EST1 compared to HFrEF ($p=0.049$, Table 2).

After three weeks of CVR the second EST (EST2) was performed. Results were similar to EST1. Namely, patients with mildly reduced and preserved LVEF showed better strain tolerance compared to patients with reduced LVEF by reaching a higher strain levels and longer duration of EST. On the other hand, arrhythmias were more present in HFrEF compared to HFpEF and HFmrEF (Table 3).

However, all three groups showed better strain tolerance at the EST2. Namely, they all reached higher strain level (for all three groups $p=0.000$) and longer duration of EST (for all three groups $p=0.000$). Also, in all three groups significantly higher percentage of patients reached submaximal heart rate at the EST2 compared to EST1 ($p=0.001$ for HFrEF, $p=0.006$ for HFmrEF, and $p=0.000$ for HFpEF), but only patients with HFrEF had higher values of double product at the end of EST2 compared to the end of EST1 (0.031). On the other hand, patients with HFrEF had a significantly higher rate of

arrhythmia at the EST2 compared to patients with mildly reduced and preserved LVEF ($p=0.009$) (Table 4). Improvement of physical strain level and duration of EST2 compared with EST1 was more pronounced in patients with reduced (by 19,2% and 28,7%), than in patients with mildly reduced (by 13,9% and 17,5%) and patients with preserved LVEF (14,1% and 16,8%).

Discussion

A well-designed CVR includes exercise training, dietary advices, psychosocial support, patient education, control of modifiable cardiovascular and non-cardiovascular risk factors and adequate medication therapy⁸. It is known that personalized and well-organized CVR may lead to the better lipid profile, anxiety and depression reduction, better blood pressure control, reduction in hospitalization and mortality rate⁹. These positive effects of CVR are shown in patients with arterial hypertension, valvular heart diseases, coronary artery disease, and heart failure. This is why all recent and relevant Guidelines advice CVR in secondary prevention of cardiovascular diseases giving it a IA recommendation^{1,10-13}.

Interestingly, the first Guideline which emphasized the importance of CVR in secondary cardiovascular

Table 3. The second exercise stress test (EST2)

EF ≤40%	Groups			Total	χ ²	P	
	41%-49%	≥50%					
Level	2.36±0.82	2.62±0.99	2.67±0.96	2.62±0.96	8.427	.015	
Duration (min)	5.56±2.28	6.35±2.78	6.45±2.74	6.33±2.72	8.055	.018	
DP before	9409.94±2122.07	9717.66±1804.27	9641.4±2091.13	9640.57±2012.82	1.713	.425	
DP after	20112.86±3554.76	21835.98±3807.56	21929.65±3690.82	21717.51±3747.32	16.521	.000	
SHR achieved n (%)	No	31 (36.9%)	83 (33.74%)	153 (30.72%)	267 (32.25%)	1.615	0.446
	Yes	53 (63.1%)	163 (66.26%)	345 (69.28%)			
Arrhythmia n (%)	No	47 (81.03%)	140 (86.42%)	310 (92.54%)	497 (89.55%)	9.385	.009
	Yes	11 (18.97%)	22 (13.58%)	25 (7.46%)			
Ischemic changes n (%)	No	77 (91.67%)	213 (86.59%)	427 (85.74%)	717 (86.59%)	2.173	.337
	Yes	7 (8.33%)	33 (13.41%)	71 (14.26%)			

DP – double product; SHR – submaximal heart rate.

Table 4. Comparison between the first and the second exercise stress test in men

EF		≤40%			41%-49%			≥50%		
		M±SD	Z/ χ^2	P	M±SD	Z/ χ^2	p	M±SD	Z/ χ^2	p
EST1 Level		1.98±0.86	-4.326 ^c	.000	2.3±0.91	-6.404 ^c	.000	2.34±0.99	-9.366 ^c	.000
EST2 Level		2.36±0.82			2.62±0.99			2.67±0.96		
EST1 duration		4.32±2.43	-5.818 ^c	.000	5.42±2.48	-8.959 ^c	.000	5.52±2.69	-11.584 ^c	.000
EST2 duration		5.56±2.28			6.35±2.78			6.45±2.74		
EST1 DP before		9704.29±2030.22	-1.066 ^d	.286	10113.58±5310.56	-.701 ^d	.483	9926.81±6664.13	-.266 ^c	.790
EST2 DP before		9409.94±2122.07			9717.66±1804.27			9641.4±2091.13		
EST1 DP after		19109.35±4272.01	-2.163 ^c	.031	22233.87±13138.37	-1.715 ^c	.086	21681.51±4005.08	-1.184 ^c	.236
EST2 DP after		20112.86±3554.76			21835.98±3807.56			21929.65±3690.82		
SHR	EST1	37 (44.05%)	6.126	0.013	143 (58.13%)	3.458	0.063	289 (58.03%)	13.609	0.000
	EST2	53 (63.1%)			163 (66.26%)			345 (69.28%)		
Arrhythmia n (%)	EST1	6 (10.53%)	1.625	0.202	17 (10.63%)	0.660	0.416	30 (8.88%)	0.448	0.503
	EST2	11 (18.97%)			22 (13.58%)			25 (7.46%)		
ST depression n (%)	EST1	4 (4.76%)	0.876	0.349	26 (10.61%)	0.912	0.340	64 (12.85%)	0.420	0.517
	EST2	7 (8.33%)			33 (13.41%)			71 (14.26%)		

prevention was the one about the diagnosis and treatment of chronic heart failure back in 2008¹⁴. Cardiac rehabilitation is of tremendous importance in HF patients as it may improve the quality of life, functional capacity and cardiac function. These beneficial effects are recognized in center-based, home-based and hybrid (short term center-based and then home-based) cardiac rehabilitation¹⁵. It seems that high-intensity interval training in HF leads to better exercise capacity. A meta-analysis which included 24 studies with CAD, HFrEF or HFpEF patients showed a significantly greater improvement in VO₂ peak after high-intensity exercise compared to moderate-intensity continuous training (by 1.40 mL/min/kg; 95% confidence interval (CI) 0.69–2.11; P ≤0.001)¹⁶. However, in the SMARTEX-HF study which included 261 NYHA II-III HFrEF patients, high-intensity training wasn't superior to moderate-intensity continuous training¹⁷. Nevertheless, both types of exercise training did lead to better strain tolerance in HF patients.

Although beneficial effect of CVR are well-known, patients with HF seldom attend cardiac rehabilitation programs. Even in HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial, which was the largest trial of CVR in patients with HFrEF, the long-term adherence was below 30%⁽¹⁸⁾. There are many factors that led to these disappointing results. One of the most important was physician inertia⁽⁹⁾. There is no doubt that stronger physician endorsement can significantly increase the participation of HF patients in CVR programs.

Both, HFrEF and HFpEF, are characterized by reduced physical tolerance and chronic fatigue. HFpEF patients suffer from exercise intolerance due to vascular, skeletal muscle, and cardiac abnormalities¹⁹. A personalized moderate to high-intensity training in these patients can increase VO₂ peak, quality of life and exercise stress tolerance¹⁹. Many studies have shown the beneficial effects of well-designed CVR on physical strain tolerance in patients with HFpEF and HFrEF. These positive effects CVR was shown regardless of age, sex, comorbidities,

and frailty²⁰. However, there is no study which investigated the effects of CVR on patients with HFmrEF.

In our study, CAD patients with HFpEF had the best strain tolerance on the first and on the second EST. The worst exercise strain tolerance was noted in CAD patients with HFrEF. These findings were somewhat expected. However, in our study all three classes of HF showed a significant improvement of exercise stress tolerance after finishing a three-week rehabilitation program. Moreover, the greatest improvement was noted in CAD patients with HFrEF. These results, once again, emphasize the importance of CVR in patients with HF.

Conclusion

Results indicate that cardiovascular rehabilitation significantly improves physical strain tolerance in patients with coronary artery diseases independent of ejection fraction. In patients with HFmrEF and patients with HFpEF cardiovascular rehabilitation resulted in higher level of strain tolerance than in patients with HFrEF. However, improvement in exercise capacity was more pronounced in patients with HFrEF.

References

- McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021; 42(36): 3599-3726.
- van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. *Eur J Heart Fail* 2016;18:242252.
- Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. *Eur Heart J* 2004;25:16141619.
- Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and

- Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. *Circulation* 2005;111(3):369-376.
5. Ilić MD, Kocić G, Lazarević G, et al. Exercise training and inflammatory markers in coronary artery disease patients. *Acta Facultatis Medicæ Naissensis* 2022; 39(2): 294-309.
 6. Stojanović M, Deljanin-Ilić M, Ilić S, Petrović D, Ilić B. The effects of cardiac rehabilitation on haemodynamic parameters measured by impedance cardiography in patients with coronary artery disease. *Vojnosanitetski pregljed* 2022;79(5):419-426.
 7. Deljanin-Ilić M, Stojanović M, Ilić S. The effect of cardiovascular rehabilitation on physical strain tolerance—does gender really matter?. *Vojnosanitetski pregljed* 2021; 78(8): 844-850.
 8. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2020:2047487320913379.
 9. Bozkurt B, Fonarow GC, Goldberg LR, et al.; ACC's Heart Failure and Transplant Section and Leadership Council. Cardiac rehabilitation for patients with heart failure: JACC Expert Panel. *J Am Coll Cardiol* 2021;77(11):1454-1469.
 10. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;37:2315–2381.
 11. Ibanez B, James S, Agewall S, et al.; ESCS scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction inpatients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;39:119–177.
 12. Neumann FJ, Sousa-Uva M, Ahlsson A, et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87–165.
 13. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;41:407–477.
 14. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur J Heart Fail* 2008;10:933–989.
 15. Imran HM, Baig M, Erqou S, et al. Home-based cardiac rehabilitation alone and hybrid with center-based cardiac rehabilitation in heart failure: A systematic review and meta-analysis. *J Am Heart Assoc* 2019; 8(16): e012779.
 16. Pattyn N, Beulque R, Cornelissen V. Aerobic interval vs. continuous training in patients with coronary artery disease or heart failure: an updated systematic review and meta-analysis with a focus on secondary outcomes. *Sports Med* 2018;48:1189–1205.
 17. Ellingsen Ø, Halle M, Conraads V, et al.; SMARTX Heart Failure Study (Study of Myocardial Recovery After Exercise Training in Heart Failure) Group. High-intensity interval training in patients with heart failure with reduced ejection fraction. *Circulation* 2017;135:839–849.
 18. O'Connor CM, Whellan DJ, Lee KL, et al.; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA* 2009;301(14):1439-1350.
 19. Tucker WJ, Angadi SS, Haykowsky MJ, Nelson MD, Sarma S, Tomczak CR. Pathophysiology of exercise intolerance and its treatment with exercise-based cardiac rehabilitation in heart failure with preserved ejection fraction. *J Cardiopulm Rehabil Prev* 2020;40(1):9-16.
 20. Kamiya K, Sato Y, Takahashi T, et al. Multidisciplinary cardiac rehabilitation and long-term prognosis in patients with heart failure. *Circ Heart Fail* 2020;13(10):e006798.

Sažetak

Efekte kardiovaskularne rehabilitacije kod pacijenata sa smanjenom, blago smanjenom i očuvanom ejectionom frakcijom – da li je korist ista za sve?

Milovan Stojanović^{1,2}, Marina Deljanin Ilić Marina^{1,2}, Stevan Ilić³

¹Institut za lečenje i rehabilitaciju Niška Banja, Srbija, ²Medicinski fakultet, Univerzitet u Nišu, Srbija, ³Klinika za interne bolesti CardioPoint, Niš, Srbija

Uvod. Koronarna arterijska bolest (KAB) je vodeći uzrok srčane insuficijencije (SI). Pozitivni efekti kardiovaskularne rehabilitacije (KVR) kod pacijenata sa KAB su dobro poznati, ali je nepoznato da li zavise od ejectione frakcije (EF). Cilj ovog rada je bio da se ispita da li bolesnici sa KAB i redukovanom, blago redukovanom i očuvanom EF imaju jednaku korist od KVR u smislu tolerancije napora.

Metode. 828 pacijenata sa KB je pohađalo tronedeljni program KVR. Pre započinjanja KVR svi pacijenti su podvrgnuti ehokardiografskom pregledu nakon čega su bolesnici podeljeni u tri grupe: srčana insuficijencija sa smanjenom (engl. HFrEF≤40%), blago smanjenom (engl. HFmrEF 41-49%) i očuvanom EF (engl. HFpEF≥50%). Na početku i na kraju KVR urađen je test fizičkim opterećenjem (TFO).

Rezultati. Bilo je 84 HFrEF (10,14%), 246 HFmrEF (29,71%) i 498 HFpEF (60,15%). Na prvom TFO (TFO1) i na drugom TFO (TFO2) HFpEF i HFmrEF pacijenti su pokazali bolju toleranciju fizičkog napora u poređenju sa bolesnicima sa HFrEF dostizanjem viših nivoa opterećenja i dužim trajanjem TFO. Međutim, sve tri grupe su pokazale bolju toleranciju napora na TFO2. Naime, svi su dostigli viši nivo opterećenja (za sve tri grupe p=0,000) i duže trajanje TFO2 (za sve tri grupe p=0,000). Takođe, u sve tri grupe značajno veći procenat pacijenata je dostigao submaksimalnu srčanu frekvencu na TFO2 u odnosu na TFO1 (p=0,001 za HFrEF, p=0,006 za HFmrEF i p=0,000 za HFpEF). Bolesnici sa HFrEF su imali češće aritmije na TFO2 u poređenju sa bolesnicima sa HFmrEF i HFpEF (p=0,009).

Zaključak. Rezultati pokazuju da je KVR značajno poboljšala toleranciju fizičkog napora kod pacijenata sa oboljenjem koronarnih arterija nezavisno od ejectione frakcije. Kod pacijenata sa HFmrEF i HFpEF KVR je doprinela višem nivou tolerancije napora u poređenju sa HFrEF bolesnicima. Međutim, sveukupno poboljšanje tolerancije napora bilo je izraženije kod pacijenata sa HFrEF.

Ključne reči: koronarna bolest, srčana slabost, kardiovaskularna rehabilitacija